ALD518 – Clinical trials

A phase I clinical trial showed ALD518 was well tolerated and could reverse fatigue in cancer patients. A phase II trial for advanced cancer is due to end in Oct 2009. Results due June 2010. Results from 124 non-small cell lung cancer (NSCLC) patients were favourable (eg.

Cancer

A phase I clinical trial showed ALD518 was well tolerated and could reverse fatigue in cancer patients.

A phase II trial for advanced cancer is due to end in Oct 2009. Results due June 2010. Results from 124 non-small cell lung cancer (NSCLC) patients were favourable (eg. 1/10th the weight loss).

Rheumatoid arthritis

The Phase IIa trial for rheumatoid arthritis has completed with promising results leading to a licencing deal allowing phase III trials. The results are to be presented in June 2010 at the European League Against Rheumatism (EULAR) meeting in Rome.


Adapted from the Wikipedia article ALD518, under the G. N. U. Free Documentation License. Please also see http://en.wikipedia.org/wiki








If you enjoyed this article, please consider sharing it!
Delicious Mixx StumbleUpon Digg

Related Articles

HepatitisEltrombopag has been studied, and shown to be effective, in two major clinical syndromes: idiopathic thrombocytopenic purpura and cirrhosis due to hep...
lupus rheumatoid arthritisPhase I clinical trials were conducted by Parexel at an independent clinical trials unit in leased space on the premises of Northwick Park and St. Mar...
RheumatoidALD518 an asialated, humanized monoclonal antibody against interleukin-6. It is an investigational drug for cancer and rheumatoid arthritis due to its...
Canadian_pharmacyBy: Lynn Woods A large stage three trial of an experimental rheumatoid arthritis medication, tasocitinib, has met two important goals – the drug pro...
Pain_relief_for_arthritisBy: Parry P Perhaps one of the best kept secrets for pain relief from arthritis is a micro-trace mineral known as Germanium. This gift from Nature hel...
Go To Top »